High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Open accessThe DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index.
Abstract
CRISPR-Cas9 nucleases are widely used for genome editing but can induce unwanted off-target mutations. Existing strategies for reducing genome-wide off-target effects of the widely used Streptococcus pyogenes Cas9 (SpCas9) are imperfect, possessing only partial or unproven efficacies and other limitations that constrain their use. Here we describe SpCas9-HF1, a high-fidelity variant harbouring alterations designed to reduce non-specific DNA contacts. SpCas9-HF1 retains on-target activities comparable to wild-type SpCas9 with >85% of single-guide RNAs (sgRNAs) tested in human cells. Notably, with sgRNAs targeted to standard non-repetitive sequences, SpCas9-HF1 rendered all or nearly all off-target events undetectable by genome-wide break capture and targeted sequencing methods. Even for atypical, repetitive target sites, the vast majority of off-target mutations induced by wild-type SpCas9 were not detected with SpCas9-HF1. With its exceptional precision, SpCas9-HF1 provides an alternative to wild-type SpCas9 for research and therapeutic applications. More broadly, our results suggest a general strategy for optimizing genome-wide specificities of other CRISPR-RNA-guided nucleases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Precision editing of alleles in a human cell has drastically improved the understanding of genotypic and phenotypic effects in gene therapy due to the lower off-target rates [119,120,121].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To address off-target issues, using the CRISPR system in the form of a rRNP and utilizing high-fidelity CRISPR variants can help minimize off-target effects (Kleinstiver et al., 2016).”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Kleinstiver et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Kleinstiver et al. developed the high-fidelity SpCas9-HF1, a variant that produced undetectable genome-wide off-target cleavage [134].”
From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [134]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In addition, a series of optimized mutations in SpCas9 have greatly improved the editing specificity of Cas9 variants without substantially attenuating the editing activity.”
From Machine learning-based prediction models to guide the selection of Cas9 variants for efficient gene editing (2024) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“Some active gRNAs for SpCas9-WT showed very low editing ability in SpCas9 variants.”
From Machine learning-based prediction models to guide the selection of Cas9 variants for efficient gene editing (2024) · cites this paper as [19]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kearse, M., Moir, R., Wilson, A., Stones-Havas, S., Cheung, M., Sturrock, S., Buxton, S., Cooper, A., Markowitz, S., Duran, C., et al. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts199 · Cited by 20,027
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.038 · Cited by 4,761
Self-citationDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Self-citation
Cited by
Items 201–300 of 1,016
DNA-based memory devices for recording cellular events
Sheth, R. U., & Wang, H. H. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0052-8 · Cited by 172
Perspectives on the Application of Genome-Editing Technologies in Crop Breeding
Hua, K., Zhang, J., Botella, J. R., Ma, C., Kong, F., Liu, B., & Zhu, J.-K. (2019) · Molecular Plant · doi:10.1016/j.molp.2019.06.009 · Cited by 166
Willems, J., de Jong, A. P. H., Scheefhals, N., Mertens, E., Catsburg, L. A. E., Poorthuis, R. B., de Winter, F., Verhaagen, J., Meye, F. J., & MacGillavry, H. D. (2020) · PLOS Biology · doi:10.1371/journal.pbio.3000665 · Cited by 170
R-loop formation and conformational activation mechanisms of Cas9
Pacesa, M., Loeff, L., Querques, I., Muckenfuss, L. M., Sawicka, M., & Jinek, M. (2022) · Nature · doi:10.1038/s41586-022-05114-0 · Cited by 169
“As observed previously 32 , the effect was more prominent for off-target substrates containing mis-matches with the seed region of the guide RNA compared with off-targets containing only PAM-distal mismatches.”
BackgroundPrecision genome editing using cytosine and adenine base editors in mammalian cells
Huang, T. P., Newby, G. A., & Liu, D. R. (2021) · Nature Protocols · doi:10.1038/s41596-020-00450-9 · Cited by 175
Multiplexed precision genome editing with trackable genomic barcodes in yeast
Roy, K. R., Smith, J. D., Vonesch, S. C., Lin, G., Tu, C. S., Lederer, A. R., Chu, A., Suresh, S., Nguyen, M., Horecka, J., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4137 · Cited by 167
Precise genomic editing of pathogenic mutations in RBM20 rescues dilated cardiomyopathy
Nishiyama, T., Zhang, Y., Cui, M., Li, H., Sanchez-Ortiz, E., McAnally, J. R., Tan, W., Kim, J., Chen, K., Xu, L., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.ade1633 · Cited by 169
Peterson, B. A., Haak, D. C., Nishimura, M. T., Teixeira, P. J. P. L., James, S. R., Dangl, J. L., & Nimchuk, Z. L. (2016) · PLOS ONE · doi:10.1371/journal.pone.0162169 · Cited by 172
Evaluating and enhancing target specificity of gene-editing nucleases and deaminases
Kim, D., Luk, K., Wolfe, S. A., & Kim, J.-S. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111730 · Cited by 171
Hultquist, J. F., Schumann, K., Woo, J. M., Manganaro, L., McGregor, M. J., Doudna, J., Simon, V., Krogan, N. J., & Marson, A. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.080 · Cited by 170
Carlson-Stevermer, J., Abdeen, A. A., Kohlenberg, L., Goedland, M., Molugu, K., Lou, M., & Saha, K. (2017) · Nature Communications · doi:10.1038/s41467-017-01875-9 · Cited by 170
Balderston, S., Taulbee, J. J., Celaya, E., Fung, K., Jiao, A., Smith, K., Hajian, R., Gasiunas, G., Kutanovas, S., Kim, D., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00706-z · Cited by 158
AsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicines
Zhang, L., Zuris, J. A., Viswanathan, R., Edelstein, J. N., Turk, R., Thommandru, B., Rube, H. T., Glenn, S. E., Collingwood, M. A., Bode, N. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24017-8 · Cited by 162
Genome surgery using Cas9 ribonucleoproteins for the treatment of age-related macular degeneration
Kim, K., Park, S. W., Kim, J. H., Lee, S. H., Kim, D., Koo, T., Kim, K.-E., Kim, J. H., & Kim, J.-S. (2017) · Genome Research · doi:10.1101/gr.219089.116 · Cited by 163
Ahmad, S., Wei, X., Sheng, Z., Hu, P., & Tang, S. (2019) · Briefings in Functional Genomics · doi:10.1093/bfgp/elz041 · Cited by 182
Latella, M. C., Di Salvo, M. T., Cocchiarella, F., Benati, D., Grisendi, G., Comitato, A., Marigo, V., & Recchia, A. (2016) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2016.92 · Cited by 165
Patterns of CRISPR/Cas9 activity in plants, animals and microbes
Bortesi, L., Zhu, C., Zischewski, J., Perez, L., Bassié, L., Nadi, R., Forni, G., Lade, S. B., Soto, E., Jin, X., et al. (2016) · Plant Biotechnology Journal · doi:10.1111/pbi.12634 · Cited by 161
Raschmanová, H., Weninger, A., Glieder, A., Kovar, K., & Vogl, T. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.01.006 · Cited by 164
Generating mouse models for biomedical research: technological advances
Gurumurthy, C. B., & Lloyd, K. C. K. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.029462 · Cited by 180
“…is constantly being improved to make it increasingly efficient and versatile, including optimizing and improving the efficiency of existing Cas nucleases (Kleinstiver et al., 2016; Slaymaker et al., 2016), and the development of novel Cas nucleases (Shmakov et al., 2015; Zetsche et al., 2015).”
BackgroundCRISPR/Cas precision: do we need to worry about off-targeting in plants?
Hahn, F., & Nekrasov, V. (2019) · Plant Cell Reports · doi:10.1007/s00299-018-2355-9 · Cited by 162
CRISPR-mediated genome editing in non-conventional yeasts for biotechnological applications
Cai, P., Gao, J., & Zhou, Y. J. (2019) · Microbial Cell Factories · doi:10.1186/s12934-019-1112-2 · Cited by 168
Unbiased investigation of specificities of prime editing systems in human cells
Kim, D. Y., Moon, S. B., Ko, J.-H., Kim, Y.-S., & Kim, D. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa764 · Cited by 157
Lau, C.-H., & Suh, Y. (2017) · F1000Research · doi:10.12688/f1000research.11243.1 · Cited by 161
CRISPR/Cas9 in insects: Applications, best practices and biosafety concerns
Taning, C. N. T., Eynde, B. V., Yu, N., Ma, S., & Smagghe, G. J. (2017) · Journal of Insect Physiology · doi:10.1016/j.jinsphys.2017.01.007 · Cited by 170
Cryo-EM structures reveal coordinated domain motions that govern DNA cleavage by Cas9
Zhu, X., Clarke, R., Puppala, A. K., Chittori, S., Merk, A., Merrill, B. J., Simonović, M., & Subramaniam, S. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0258-2 · Cited by 160
Chen, F., Ding, X., Feng, Y., Seebeck, T., Jiang, Y., & Davis, G. D. (2017) · Nature Communications · doi:10.1038/ncomms14958 · Cited by 157
Type II-C CRISPR-Cas9 Biology, Mechanism, and Application
Mir, A., Edraki, A., Lee, J., & Sontheimer, E. J. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b00855 · Cited by 145
Knowles, J. K., Helbig, I., Metcalf, C. S., Lubbers, L. S., Isom, L. L., Demarest, S., Goldberg, E. M., George, A. L., Lerche, H., Weckhuysen, S., et al. (2022) · Epilepsia · doi:10.1111/epi.17332 · Cited by 166
Lei, T., Wang, Y., Zhang, Y., Yang, Y., Cao, J., Huang, J., Chen, J., Chen, H., Zhang, J., wang, L., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02444-y · Cited by 175
Burnight, E. R., Gupta, M., Wiley, L. A., Anfinson, K. R., Tran, A., Triboulet, R., Hoffmann, J. M., Klaahsen, D. L., Andorf, J. L., Jiao, C., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.015 · Cited by 142
Xu, X., Tan, X., Tampe, B., Wilhelmi, T., Hulshoff, M. S., Saito, S., Moser, T., Kalluri, R., Hasenfuss, G. P., Zeisberg, E. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05766-5 · Cited by 160
Deciphering Off-Target Effects in CRISPR-Cas9 through Accelerated Molecular Dynamics
Ricci, C. G., Chen, J. S., Miao, Y., Jinek, M., Doudna, J. A., McCammon, J. A., & Palermo, G. (2019) · ACS Central Science · doi:10.1021/acscentsci.9b00020 · Cited by 145
Morgan, M. A., Büning, H., Sauer, M. G., & Schambach, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01965 · Cited by 157
Structural basis for the altered PAM specificities of engineered CRISPR-cas9
Hirano, S., Nishimasu, H., Ishitani, R., & Nureki, O. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.02.018 · Cited by 152
Pacher, M., & Puchta, H. (2017) · The Plant Journal · doi:10.1111/tpj.13469 · Cited by 145
Insert, remove or replace: A highly advanced genome editing system using CRISPR/Cas9
Ceasar, S. A., Rajan, V., Prykhozhij, S. V., Berman, J. N., & Ignacimuthu, S. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.06.009 · Cited by 151
Mitigation of off-target toxicity in CRISPR-Cas9 screens for essential non-coding elements
Tycko, J., Wainberg, M., Marinov, G. K., Ursu, O., Hess, G. T., Ego, B. K., Aradhana, Li, A., Truong, A., Trevino, A. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11955-7 · Cited by 148
Characteristics of Genome Editing Mutations in Cereal Crops
Zhu, C., Bortesi, L., Baysal, C., Twyman, R. M., Fischer, R., Capell, T., Schillberg, S., & Christou, P. (2016) · Trends in Plant Science · doi:10.1016/j.tplants.2016.08.009 · Cited by 157
Genome-wide profiling of adenine base editor specificity by EndoV-seq
Liang, P., Xie, X., Zhi, S., Sun, H., Zhang, X., Chen, Y., Chen, Y., Xiong, Y., Ma, W., Liu, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07988-z · Cited by 148
Adeno-Associated Virus Toolkit to Target Diverse Brain Cells
Challis, R. C., Ravindra Kumar, S., Chen, X., Goertsen, D., Coughlin, G. M., Hori, A. M., Chuapoco, M. R., Otis, T. S., Miles, T. F., & Gradinaru, V. (2022) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-111020-100834 · Cited by 148
CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles
Dai, W.-J., Zhu, L.-Y., Yan, Z.-Y., Xu, Y., Wang, Q.-L., & Lu, X.-J. (2016) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2016.58 · Cited by 144
Clarke, R., Heler, R., MacDougall, M. S., Yeo, N. C., Chavez, A., Regan, M. R., Hanakahi, L. A., Church, G. M., Marraffini, L. A., & Merrill, B. J. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.06.005 · Cited by 163
Non-viral delivery of the CRISPR/Cas system: DNA versus RNA versus RNP
Lin, Y., Wagner, E., & Lächelt, U. (2022) · Biomaterials Science · doi:10.1039/d1bm01658j · Cited by 155
van Agtmaal, E. L., André, L. M., Willemse, M. P., Cumming, S. A., van Kessel, I. D. G., van den Broek, W. J. A. A., Gourdon, G., Furling, D., Mouly, V., Monckton, D. G., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.014 · Cited by 153
Exploration of Plant-Microbe Interactions for Sustainable Agriculture in CRISPR Era
Shelake, R. M., Pramanik, D., & Kim, J. (2019) · Microorganisms · doi:10.3390/microorganisms7080269 · Cited by 153
Darkwa, K., Olasanmi, B., Asiedu, R., & Asfaw, A. (2019) · Plant Breeding · doi:10.1111/pbr.12783 · Cited by 166
“Some approaches such as DNA-RNA chimeric guides, Cpf1, a single RNA endonuclease that employs a T-rich PAM on the 5′ side of the guide, and specific point mutations have been developed to mitigate this limitation (Kleinstiver et al., 2016; Zetsche et al., 2016).”
BackgroundOrtinski, P. I., O’Donovan, B., Dong, X., & Kantor, B. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.04.002 · Cited by 146
Modeling Human Digestive Diseases With CRISPR-Cas9–Modified Organoids
Fujii, M., Clevers, H., & Sato, T. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.11.048 · Cited by 140
Kim, H. K., Lee, S., Kim, Y., Park, J., Min, S., Choi, J. W., Huang, T. P., Yoon, S., Liu, D. R., & Kim, H. H. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0505-1 · Cited by 145
Probing the impact of chromatin conformation on genome editing tools
Chen, X., Rinsma, M., Janssen, J. M., Liu, J., Maggio, I., & Gonçalves, M. A. F. V. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw524 · Cited by 142
Opportunities and challenges in modeling human brain disorders in transgenic primates
Jennings, C. G. B., Landman, R., Zhou, Y., Sharma, J., Hyman, J. B., Movshon, J. A., Qiu, Z., Roberts, A., Roe, A. W., Wang, X., et al. (2016) · Nature Neuroscience · doi:10.1038/nn.4362 · Cited by 151
Recent Advances in Genome Editing Using CRISPR/Cas9
Ding, Y., Li, H., Chen, L.-L., & Xie, K. (2016) · Frontiers in Plant Science · doi:10.3389/fpls.2016.00703 · Cited by 129
“…variant NGAN or NGNG Kleinstiver et al., 2015b Cas9 (N497A/R661A/Q695A/Q926A), also referred to as Cas9-HF1 NGG (no detectable off-target effects) Kleinstiver et al., 2016 Cas9 (K810A/K1003A/R1060A), also referred to as eSpCas9 (1.0) NGG (reduces off-target effects and maintains robust on-target…”
BackgroundInfluentialCebrian-Serrano, A., & Davies, B. (2017) · Mammalian Genome · doi:10.1007/s00335-017-9697-4 · Cited by 154
The chemistry of Cas9 and its CRISPR colleagues
Chen, J. S., & Doudna, J. A. (2017) · Nature Reviews Chemistry · doi:10.1038/s41570-017-0078 · Cited by 152
CRISPR-Cas in Streptococcus pyogenes
Rhun, A. L., Escalera-Maurer, A., Bratovič, M., & Charpentier, E. (2019) · RNA Biology · doi:10.1080/15476286.2019.1582974 · Cited by 162
Wei, T., Cheng, Q., Farbiak, L., Anderson, D. G., Langer, R., & Siegwart, D. J. (2020) · ACS Nano · doi:10.1021/acsnano.0c04707 · Cited by 135
Kumlehn, J., Pietralla, J., Hensel, G., Pacher, M., & Puchta, H. (2018) · Journal of Integrative Plant Biology · doi:10.1111/jipb.12734 · Cited by 153
DNA stretching induces Cas9 off-target activity
Newton, M. D., Taylor, B. J., Driessen, R. P. C., Roos, L., Cvetesic, N., Allyjaun, S., Lenhard, B., Cuomo, M. E., & Rueda, D. S. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0188-z · Cited by 138
Barriers to genome editing with CRISPR in bacteria
Vento, J. M., Crook, N., & Beisel, C. L. (2019) · Journal of Industrial Microbiology and Biotechnology · doi:10.1007/s10295-019-02195-1 · Cited by 143
Wang, Y., Zafar, N., Ali, Q., Manghwar, H., Wang, G., Yu, L., Ding, X. L., Ding, F., Hong, N., Wang, G., et al. (2022) · Cells · doi:10.3390/cells11233928 · Cited by 168
Long Terminal Repeat CRISPR-CAR-Coupled “Universal” T Cells Mediate Potent Anti-leukemic Effects
Georgiadis, C., Preece, R., Nickolay, L., Etuk, A., Petrova, A., Ladon, D., Danyi, A., Humphryes-Kirilov, N., Ajetunmobi, A., Kim, D., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.025 · Cited by 137
An Outlook on Global Regulatory Landscape for Genome-Edited Crops
Ahmad, A., Munawar, N., Khan, Z., Qumsani, A. T., Khan, S. H., Jamil, A., Ashraf, S., Ghouri, M. Z., Aslam, S., Mubarik, M. S., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111753 · Cited by 154
An In Vivo Kras Allelic Series Reveals Distinct Phenotypes of Common Oncogenic Variants
Zafra, M. P., Parsons, M. J., Kim, J., Alonso-Curbelo, D., Goswami, S., Schatoff, E. M., Han, T., Katti, A., Fernandez, M. T. C., Wilkinson, J. E., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0442 · Cited by 139
CRISPR/dCas9-Based Systems: Mechanisms and Applications in Plant Sciences
Karlson, C. K. S., Noor, S. N. M., Nolte, N., & Tan, B. C. (2021) · Plants · doi:10.3390/plants10102055 · Cited by 157
“Other modified Cas9 proteins, such as enhanced-specificity eSpCas9 variant [66], hyper-accurate Cas9 variant, HypaCas9 [67] and high-fidelity SpCas9-HF1 [68], have also been reported.”
In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice
El Refaey, M., Xu, L., Gao, Y., Canan, B. D., Adesanya, T. M. A., Warner, S. C., Akagi, K., Symer, D. E., Mohler, P. J., Ma, J., et al. (2017) · Circulation Research · doi:10.1161/circresaha.117.310996 · Cited by 136
Cardiac Pathophysiology and the Future of Cardiac Therapies in Duchenne Muscular Dystrophy
Meyers, T. A., & Townsend, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174098 · Cited by 149
“The risk of off-target editing can be managed by optimizing both the guide RNAs and the Cas9 endonucleases to minimize non-specific activity and improve fidelity [190,200].”
Genome Editing in Cereals: Approaches, Applications and Challenges
Ansari, W. A., Chandanshive, S. U., Bhatt, V. D., Nadaf, A. B., Vats, S., Katara, J. L., Sonah, H., & Deshmukh, R. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114040 · Cited by 146
“To overcome these limitations, variants of cas9 have been obtained in which high fidelity Cas9 holds mutations that decreases the interaction between non-specific DNA and nuclease domain which ultimately reduces off target effects [55].”
BackgroundKhoshandam, M., Soltaninejad, H., Mousazadeh, M., Hamidieh, A. A., & Hosseinkhani, S. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.027 · Cited by 153
Promoting Cas9 degradation reduces mosaic mutations in non-human primate embryos
Tu, Z., Yang, W., Yan, S., Yin, A., Gao, J., Liu, X., Zheng, Y., Zheng, J., Li, Z., Yang, S., et al. (2017) · Scientific Reports · doi:10.1038/srep42081 · Cited by 129
Dead Cas Systems: Types, Principles, and Applications
Brezgin, S. A., Kostyusheva, A. P., Kostyushev, D. S., & Chulanov, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236041 · Cited by 140
“To reduce or even avoid potential off-target activity, a plethora of technical refinements has been made, including (a) advanced design of gRNAs using in situ CRISPR-Cas design tools (CRISPR design, E-Crisp, CROP-IT, Cas-OFFinder) [178], (b) modifications of gRNAs (truncations [179], introduction of secondary structur…”
BackgroundCRISPR/Cas9‐mediated genome editing: From basic research to translational medicine
Jacinto, F. V., Link, W., & Ferreira, B. I. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14916 · Cited by 148
Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing
Han, H. A., Pang, J. K. S., & Soh, B.-S. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01893-z · Cited by 134
“1)), the Cas9 affinity for non-targeted sequences is diminished and the resulting Cas9 variants showed reduced OTEs [70, 71].”
BackgroundIn Silico Meets In Vivo : Towards Computational CRISPR-Based sgRNA Design
Chuai, G., Wang, Q., & Liu, Q. (2016) · Trends in biotechnology · doi:10.1016/j.tibtech.2016.06.008 · Cited by 143
Engineering CRISPR–Cpf1 crRNAs and mRNAs to maximize genome editing efficiency
Li, B., Zhao, W., Luo, X., Zhang, X., Li, C., Zeng, C., & Dong, Y. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0066 · Cited by 136
Crossing enhanced and high fidelity SpCas9 nucleases to optimize specificity and cleavage
Kulcsár, P. I., Tálas, A., Huszár, K., Ligeti, Z., Tóth, E., Weinhardt, N., Fodor, E., & Welker, E. (2017) · Genome Biology · doi:10.1186/s13059-017-1318-8 · Cited by 130
Zhang, D., Zhang, H., Li, T., Chen, K., Qiu, J.-L., & Gao, C. (2017) · Genome Biology · doi:10.1186/s13059-017-1325-9 · Cited by 134
Weninger, A., Fischer, J. E., Raschmanová, H., Kniely, C., Vogl, T., & Glieder, A. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26474 · Cited by 139
Massively parallel kinetic profiling of natural and engineered CRISPR nucleases
Jones, S. K., Hawkins, J. A., Johnson, N. V., Jung, C., Hu, K., Rybarski, J. R., Chen, J. S., Doudna, J. A., Press, W. H., & Finkelstein, I. J. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0646-5 · Cited by 136
Evaluation and Reduction of CRISPR Off-Target Cleavage Events
Vakulskas, C. A., & Behlke, M. A. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.0790 · Cited by 119
Versatile detection with CRISPR/Cas system from applications to challenges
Wu, H., Chen, X., Zhang, M., Wang, X., Chen, Y., Qian, C., Wu, J. F., & Xu, J. (2020) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2020.116150 · Cited by 132
Loureiro, A., & da Silva, G. J. (2019) · Antibiotics · doi:10.3390/antibiotics8010018 · Cited by 129
“developed the high-fidelity SpCas9-HF1, a variant that produced undetectable genome-wide off-target cleavage [134].”
BackgroundImplications of human genetic variation in CRISPR-based therapeutic genome editing
Scott, D. A., & Zhang, F. (2017) · Nature Medicine · doi:10.1038/nm.4377 · Cited by 129
Advances in CRISPR-Cas systems for RNA targeting, tracking and editing
Wang, F., Wang, L., Zou, X., Duan, S., Li, Z., Deng, Z., Luo, J., Lee, S. Y., & Chen, S. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.03.016 · Cited by 128
Wang, L., Wang, L., Tan, Q., Fan, Q., Zhu, H., Hong, Z., Zhang, Z., & Duanmu, D. (2016) · Frontiers in Plant Science · doi:10.3389/fpls.2016.01333 · Cited by 126
CRISPR/Cas9 for Cancer Therapy: Hopes and Challenges
Martínez-Lage, M., Puig-Serra, P., Menéndez, P. R., Torres-Ruiz, R., & Rodríguez, S. (2018) · Biomedicines · doi:10.3390/biomedicines6040105 · Cited by 141
“Finally, mutational analysis of Cas9 to increase its specificity has shown that 3–4 engineered point mutations are able to neutralize nonspecific electrostatic interactions between Cas9 and its target DNA, significantly increasing the specificity of its action [40,41].”
BackgroundNmeCas9 is an intrinsically high-fidelity genome-editing platform
Amrani, N., Gao, X. D., Liu, P., Edraki, A., Mir, A., Ibraheim, R., Gupta, A., Sasaki, K. E., Wu, T., Donohoue, P. D., et al. (2018) · Genome Biology · doi:10.1186/s13059-018-1591-1 · Cited by 125
Metabolic engineering of plant secondary metabolites: prospects and its technological challenges
Devi, A. M., Devi, K. K., Pukhrambam, P. D., Devi, M. L., & Das, S. (2023) · Frontiers in Plant Science · doi:10.3389/fpls.2023.1171154 · Cited by 144
Gene therapy and genome surgery in the retina
DiCarlo, J. E., Mahajan, V. B., & Tsang, S. H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120429 · Cited by 127
AAV-mediated CRISPR/cas gene editing of retinal cells in vivo
Hung, S. S. C., Chrysostomou, V., Li, F., Lim, J. K. H., Wang, J.-H., Powell, J. E., Tu, L., Daniszewski, M., Lo, C., Wong, R. C., et al. (2016) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.16-19316 · Cited by 125
Editing the genome of hiPSC with CRISPR/Cas9: disease models
Bassett, A. R. (2017) · Mammalian Genome · doi:10.1007/s00335-017-9684-9 · Cited by 109
Efficient mouse genome engineering by CRISPR-EZ technology
Modzelewski, A. J., Chen, S., Willis, B. J., Lloyd, K. C. K., Wood, J. A., & He, L. (2018) · Nature Protocols · doi:10.1038/nprot.2018.012 · Cited by 126
Jackow, J., Guo, Z., Hansen, C. S., Abaci, H. E., Doucet, Y., Shin, J. U., Hayashi, R., DeLorenzo, D., Kabata, Y., Shinkuma, S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1907081116 · Cited by 131
CRISPR/Cas-Based Epigenome Editing: Advances, Applications, and Clinical Utility
Goell, J., & Hilton, I. B. (2021) · Trends in biotechnology · doi:10.1016/j.tibtech.2020.10.012 · Cited by 136
Hultquist, J. F., Hiatt, J., Schumann, K., McGregor, M. J., Roth, T. L., Haas, P., Doudna, J. A., Marson, A., & Krogan, N. J. (2019) · Nature Protocols · doi:10.1038/s41596-018-0069-7 · Cited by 125
Mechanisms of improved specificity of engineered Cas9s revealed by single-molecule FRET analysis
Singh, D., Wang, Y., Mallon, J., Yang, O., Fei, J., Poddar, A., Ceylan, D., Bailey, S., & Ha, T. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0051-7 · Cited by 121
Palermo, G., Chen, J. S., Ricci, C. G., Rivalta, I., Jinek, M., Batista, V. S., Doudna, J. A., & McCammon, J. A. (2018) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583518000070 · Cited by 123
“Considering the key role of the REC lobe in the specificity of Cas9 (Casini et al., 2018; Chen et al., 2017; Kleinstiver et al., 2016), this study provides the foundation for understanding how the REC lobe domains control the cleavage of off-target sequences.”
BackgroundAlić, I., Goh, P. A., Murray, A., Portelius, E., Gkanatsiou, E., Gough, G., Mok, K. Y., Koschut, D., Brunmeir, R., Yeap, Y. J., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0806-5 · Cited by 123
“Using CRISPR/SpCas9-HF1, we eliminated a single copy of BACE2 in the trisomic iPSC clone C5 (T21C5Δ7, a Δ7 bp in BACE2 exon3, knocking out one of three copies of the gene), while maintaining the trisomy of the rest of chromosome 21 (Fig.”
Sherkatghanad, Z., Abdar, M., Charlier, J., & Makarenkov, V. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad131 · Cited by 129
The Self-Inactivating KamiCas9 System for the Editing of CNS Disease Genes
Merienne, N., Vachey, G., de Longprez, L., Meunier, C., Zimmer, V., Perriard, G., Canales, M., Mathias, A., Herrgott, L., Beltraminelli, T., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.075 · Cited by 115
CRISPR/Cas9 Genome-Editing System in Human Stem Cells: Current Status and Future Prospects
Zhang, Z., Zhang, Y., Gao, F., Han, S., Cheah, K. S., Tse, H.-F., & Lian, Q. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2017.09.009 · Cited by 114
Metadata
- Authors
- Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- City University of Hong Kong (HK)
- Corresponding author
- Joung, J. Keith
- ORCID
- Venue
- Nature
- Published
- 2016-01-06
- Volume
- 529
- Issue
- 7587
- Pages
- 490-495
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4851738
- OpenAlex
- W2224398381
- Cited by
- 2,673
- References
- 47
- Citations by year
- 2026: 189 · 2025: 221 · 2024: 200 · 2023: 181 · 2022: 267 · 2021: 273 · 2020: 287 · 2019: 284 · 2018: 284 · 2017: 267 · 2016: 215
- FWCI
- 181.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of General Medical Sciences (DP1GM105378, R01GM107427, R01GM088040)
- National Center for Chronic Disease Prevention and Health Promotion (DP1 GM105378)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- CRISPR/Cas9, off-target mutations, Streptococcus pyogenes, single guide RNA, targeted sequencing, genome editing
- MeSH terms
- Base Sequence, DNA, DNA-Binding Proteins, Endonucleases, Genetic Engineering, Humans, Mutation, Protein Binding, RNA, Streptococcus pyogenes, Substrate Specificity, Reproducibility of Results, Genome, Human, Sequence Analysis, DNA, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.